Drugs that contain Sodium Oxybate
1. Lumryz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11052061 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10952986 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11602513 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10272062 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11000498 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11400065 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Jul, 2037
(13 years from now) | |
| US11826335 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11839597 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11065224 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10973795 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11504347 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11602512 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10736866 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11766418 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10925844 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Feb, 2040
(15 years from now) | |
| US11583510 | AVADEL CNS | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Feb, 2042
(17 years from now) | |
| US11779557 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Mar, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| New Product(NP) | May 01, 2026 |
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of a disorder treatable with gamma-hydroxybutyrate using a single, daily dose of a gamma-hydroxybutyrate formulation; Treatment of narcolepsy-related cataplexy or excessive daytime sleepines...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
LUMRYZ family patents
2. Xyrem patents expiration
XYREM's oppositions filed in EPO
XYREM Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263650 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US9539330 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8324275 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8859619 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US8952062 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
| US7851506 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(4 years ago) | |
|
US8324275 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8263650 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US9539330 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8952062 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US8859619 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
|
US7851506 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(3 years ago) | |
| US7262219 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(3 years ago) | |
| US6780889 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(3 years ago) | |
|
US6780889 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(3 years ago) | |
|
US7262219 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(3 years ago) | |
| US8457988 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US7895059 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US8589182 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US8731963 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
|
US8731963 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
|
US8589182 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
|
US8457988 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
|
US7895059 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(10 months ago) | |
| US7765107 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
| US7765106 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
| US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
|
US7765106 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(7 months from now) | |
|
US7765107 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(7 months from now) | |
|
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(7 months from now) | |
| US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
|
US9050302 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US11253494 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9486426 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10864181 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating cataplexy in patients with narcolepsy; Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating a patient with a prescription drug using a com...
Dosage: SOLUTION;ORAL
How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage
XYREM family patents